ArticleHemaSphere2021

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial.

Mathias Witzens-Harig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.